Deep Learning in Pharmacogenomics: From Gene Regulation to Patient Stratification
By Alexandr A Kalinin, Gerald A. Higgins, Narathip Reamaroon, S. M. Reza Soroushmehr, Ari Allyn-Feuer, I. Dinov, Kayvan Najarian, B. Athey. 2018
142 citations recorded by the source corpus.
This Perspective provides examples of current and future applications of deep learning in pharmacogenomics, including: identification of novel regulatory variants located in noncoding domains of the genome and their function as applied to pharmacoepigenomics; patient stratification from medical records; and the mechanistic prediction of drug response, targets and their interactions. Deep learning encapsulates a family of machine learning algorithms that has transformed many important subfields of artificial intelligence over the last decade, and has demonstrated breakthrough performance improvements on a wide range of tasks in biomedicine. We anticipate that in the future, deep learning will be widely used to predict personalized drug response and optimize medication selection and dosing, using knowledge extracted from large and complex molecular, epidemiological, clinical and demographic datasets.
Subfields: Genetics, Molecular Biology, Pharmacology
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Molecular Biology
In Pharmacology
Citations in the corpus
- An overview of deep learning in medical imaging focusing on MRI (2018, background): “seizures [17] and cardiac arrests [18], to computer-aided detection [19] and diagnosis [20] supporting clinical decision making and survival analysis [21], to drug discovery [22] and as an aid in therapy selection and pharmacogenomics [23], to increased operational efficiency [24], stratified care d”
- Angiodysplasia Detection and Localization Using Deep Convolutional Neural Networks (2018, background): “Recently, deep learning-based approaches demonstrated performance improvements over conventional machine learning methods for many problems in biomedicine [15], [16].”
- Automatic Instrument Segmentation in Robot-Assisted Surgery Using Deep Learning (2018, background): “Recently, deep learning-based approaches demonstrated performance improvements over conventional machine learning methods for many problems in biomedicine [5, 12].”
- ARTIFICIAL INTELLIGENCE AND PERSONALIZED MEDICINE (2019, background): “[31, 32] The design of phase I clinical trials is an ongoing area of research.”
- 3D Cell Nuclear Morphology: Microscopy Imaging Dataset And Voxel-Based Morphometry Classification Results (2017, methodology): “The size of the produced 3D morphological dataset should be big enough to use segmentation-free deep learning-based morphology analysis approaches [5, 15].”
- Pediatric Bone Age Assessment Using Deep Convolutional Neural Networks (2017, background): “Recently, deep learning-based approaches demonstrated performance improvements over conventional machine learning methods for many problems in biomedicine [1, 10].”